Cambia Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Cambia Availability in 2026

If your patients have been reporting difficulty filling their Cambia prescriptions, they're not wrong. While Cambia (Diclofenac Potassium for oral solution, 50 mg) is not in a formal FDA-listed shortage, real-world access remains challenging for many patients in 2026. This briefing covers what's driving the availability issues, the prescribing implications, and practical tools to help your patients get the treatment they need.

What Is Cambia?

Cambia is an NSAID formulated as a powder for oral solution, FDA-approved for the acute treatment of migraine attacks with or without aura in adults. Its liquid formulation allows for faster absorption compared to standard Diclofenac tablets, providing rapid onset of migraine relief — typically within 15-30 minutes. It is manufactured by Assertio Therapeutics.

The standard dose is one 50 mg packet dissolved in 1-2 ounces of water, taken as a single dose at migraine onset. It is not indicated for migraine prevention or for use in patients under 18.

Timeline: How We Got Here

Cambia was approved by the FDA in 2009 and has been marketed in the United States since then. Over the years, several factors have converged to create the current availability situation:

• 2009: FDA approval for acute migraine treatment
• 2014-2018: Patent protections kept prices elevated; limited formulary adoption by insurance plans
• 2019-2022: Generic Diclofenac Potassium for oral solution received FDA approval, but manufacturing and distribution remained limited
• 2023-2025: Increasing reports from patients of difficulty finding Cambia at retail pharmacies; discount card pricing began offering significant savings
• 2026: No formal shortage, but persistent functional access issues at retail pharmacies nationwide

Prescribing Implications

When prescribing Cambia, providers should be aware of several practical considerations:

Insurance and Prior Authorization

Most commercial insurance plans classify Cambia as a non-preferred brand or Tier 3 medication. Common coverage requirements include:

• Prior authorization — Documentation that the patient has tried and failed, or has contraindications to, first-line acute migraine treatments
• Step therapy — Typically requires trial of generic triptans (Sumatriptan, Rizatriptan) and/or OTC NSAIDs before approval
• Medicare Part D — Generally does not cover Cambia

If prior authorization is denied, appealing with clinical documentation of triptan contraindications (e.g., cardiovascular risk factors) or documented treatment failures can be effective.

Boxed Warning Considerations

As with all NSAIDs, Cambia carries a boxed warning for:

• Cardiovascular thrombotic events — Increased risk of MI and stroke, which may increase with duration of use
• GI bleeding, ulceration, and perforation — Can occur at any time without warning

These warnings are particularly relevant when evaluating Cambia against triptan alternatives, which carry their own cardiovascular contraindications. For patients with significant CV risk, CGRP receptor antagonists (gepants) may be the preferred alternative. For a comprehensive review of interactions, see Cambia Drug Interactions: What to Avoid.

Current Availability Picture

Cambia is not on the FDA drug shortage list as of February 2026. The manufacturer reports normal production. However, real-world availability is limited by:

• Low pharmacy stocking rates: Chain pharmacies (CVS, Walgreens, Rite Aid) rarely keep Cambia in regular inventory due to its high wholesale cost ($1,200+ per box) and low fill volume
• Wholesaler availability: Cambia is available through major wholesalers (McKesson, Cardinal Health, AmerisourceBergen); pharmacies can order it but must choose to do so
• Limited generic penetration: Despite FDA approval of a generic, widespread distribution has not materialized

Cost and Access Landscape

Understanding the cost picture helps providers set appropriate expectations with patients:

• Cash price: $1,200-$1,400 for 9 packets
• With discount card: As low as $93 for 9 packets (via SingleCare or comparable programs)
• Insured copay: Highly variable — $30-$200+ depending on plan and tier
• Manufacturer savings: Assertio Therapeutics has offered copay assistance programs; check cambiarx.com for current eligibility

Providers should routinely recommend that uninsured or underinsured patients check discount card pricing, which can reduce cost by over 90%.

Tools and Resources for Providers

Several tools can help streamline the process of getting patients their Cambia prescriptions:

Medfinder for Providers

Medfinder for Providers allows you to check real-time pharmacy availability for Cambia near your patient's location. This eliminates the guesswork of sending prescriptions to pharmacies that may not stock the medication.

Practical Workflow Tips

1. Check availability before prescribing: Use Medfinder to identify pharmacies with Cambia in stock near your patient
2. Route prescriptions to independent pharmacies: They are more likely to order specialty medications and often have shorter turnaround times
3. Include a note for the pharmacy: "Patient requires brand Cambia — Diclofenac Potassium 50 mg oral solution packets" to avoid confusion with other Diclofenac products
4. Discuss cost upfront: Inform patients about discount card options and patient assistance programs before they arrive at the pharmacy
5. Have an alternative ready: If Cambia can't be filled, know your patient's backup — typically a triptan or gepant, depending on their cardiovascular profile

Alternative Therapies to Consider

When Cambia is unavailable or inappropriate, evidence-based alternatives include:

• Sumatriptan (Imitrex): First-line triptan, widely available as generic ($10-$30/9 tablets). Contraindicated in patients with significant CV disease.
• Rizatriptan (Maxalt): Fast-onset triptan with ODT option ($15-$40/9 tablets generic)
• Ubrogepant (Ubrelvy): CGRP antagonist, suitable for patients with CV contraindications to triptans. Brand-only, ~$150-$200/dose.
• Rimegepant (Nurtec ODT): CGRP antagonist with both acute and preventive indications. Brand-only.
• Naproxen Sodium 550 mg: Prescription-strength NSAID, same mechanism class as Cambia but slower onset. Available as inexpensive generic.

For a detailed comparison, refer patients to Alternatives to Cambia If You Can't Fill Your Prescription.

Looking Ahead

The availability outlook for Cambia in 2026 and beyond depends on several factors:

• Generic market entry: If generic manufacturers begin wider distribution of Diclofenac Potassium for oral solution, prices and availability should improve
• Formulary changes: As migraine treatment guidelines evolve and newer agents gain market share, insurance formularies may shift
• Patient awareness: Tools like Medfinder are helping connect patients with available supply, which may encourage more pharmacies to stock the product

Final Thoughts

Cambia remains a clinically valuable option for acute migraine treatment, particularly for patients who prefer an NSAID approach or have contraindications to triptans. The primary barriers in 2026 are practical — cost, insurance coverage, and pharmacy stocking — rather than supply-related.

By using tools like Medfinder for Providers, discussing cost-saving strategies proactively, and maintaining awareness of alternative options, providers can help their migraine patients navigate these access challenges effectively.

Additional provider resources:

• How to Help Your Patients Find Cambia in Stock: A Provider's Guide
• How to Help Patients Save Money on Cambia: A Provider's Guide
• Cambia Side Effects: What to Expect and When to Call Your Doctor